激光间质热疗在神经肿瘤外科中的作用:100例连续患者系列
单中心单个神经外科医生2013至2018年间对脑肿瘤患者行激光间质热疗(LITT)的探索性队列研究,共91例患者接受100次手术,中位随访7.2个月时61%存活、72%局部控制,并发症率4%,消融范围预测局部控制。
要点
- 91例患者共接受100次LITT手术,中位随访7.2个月,61%存活,72%局部控制。
- 中位至复发时间(TTR)31.9个月,中位总生存期(OS)16.9个月。
- 消融范围(EOA)预测局部控制(P=.009),EOA>85%预测更长TTR(P=.006)。
核心结论
- 该LITT系列是迄今为止最大系列之一,进一步证实了其安全性和结局特征。
研究设计与样本
- 探索性队列研究,纳入2013至2018年间单中心单个资深神经外科医生治疗的所有脑肿瘤LITT患者。
- 共91例患者接受100次LITT手术,按肿瘤亚型比较结局并识别预测因素。
主要发现
- 中位随访7.2个月时61%存活,72%局部控制;中位TTR和OS分别为31.9和16.9个月。
- 硬脑膜病变(n=4):TTR不适用,1年局部控制率75%,中位OS 20.7个月。
- 转移瘤(n=45):中位TTR 55.9个月,1年局部控制率77.4%,中位OS 16.9个月。
- 新诊断胶质母细胞瘤(n=11):中位TTR 31.9个月,1年局部控制率83.3%,中位OS 32.3个月。
- 复发胶质母细胞瘤(n=14):中位TTR 5.6个月,1年局部控制率24.3%,中位OS 7.3个月;放射性坏死(n=20):TTR不适用,1年局部控制率67.2%,中位OS 16.4个月;其他病变(n=6):中位TTR 12.3个月,1年局部控制率80%,中位OS 24.4个月。
关键数值与推荐
- TTR因肿瘤亚型而异(P=.02,log-rank分析)。
- EOA预测局部控制(P=.009,多因素比例风险回归);EOA>85%预测更长TTR(P=.006,log-rank分析)。
- 并发症率为4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laser interstitial thermal therapy (LITT) is an adjuvant treatment for intracranial lesions that are treatment refractory or in deep or eloquent brain. Initial studies of LITT in surgical neuro-oncology are limited in size and follow-up. OBJECTIVE: To present our series of LITT in surgical neuro-oncology to better evaluate procedural safety and outcomes. METHODS: An exploratory cohort study of all patients receiving LITT for brain tumors by a single senior neurosurgeon at a single center between 2013 and 2018. Primary outcomes included extent of ablation (EOA), time to recurrence (TTR), local control at 1-yr follow-up, and overall survival (OS). Secondary outcomes included complication rate. Outcomes were compared by tumor subtype. Predictors of outcomes were identified. RESULTS: A total of 91 patients underwent 100 LITT procedures; 61% remain alive with 72% local control at median 7.2 mo follow-up. Median TTR and OS were 31.9 and 16.9 mo, respectively. For lesion subtypes, median TTR (months, not applicable [N/A] if <50% rate observed), local control rates at 1-yr follow-up, and median OS (months) were the following: dural-based lesions (n = 4, N/A, 75%, 20.7), metastases (n = 45, 55.9, 77.4%, 16.9), newly diagnosed glioblastoma (n = 11, 31.9, 83.3%, 32.3), recurrent glioblastoma (n = 14, 5.6, 24.3%, 7.3), radiation necrosis (n = 20, N/A, 67.2%, 16.4), and other lesions (n = 6, 12.3, 80%, 24.4). TTR differed by tumor subtype (P = .02, log-rank analysis). EOA predicted local control (P = .009, multivariate proportional hazards regression); EOA > 85% predicted longer TTR (P = .006, log-rank analysis). Complication rate was 4%. CONCLUSION: Our series of LITT in surgical neuro-oncology, 1 of the largest to date, further evidences its safety and outcomes profile.
引用
- Shah AH, Semonche A, Eichberg DG, et al. The Role of Laser Interstitial Thermal Therapy in Surgical Neuro-Oncology: Series of 100 Consecutive Patients. Neurosurgery. 2020. PMID: 31742351. doi:10.1093/neuros/nyz424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。